Prexton Therapeutics SA

Recently founded in Geneva, Switzerland, Prexton Therapeutics is developing novel mGluR4 PAM series, which were originally developed by Merck Serono, an affiliate of Merck KGaA in Darmstadt, Germany. Considerable effort has gone into creating chemical diversity of drug-like molecules with properties suitable for brain diseases, such as blood-brain barrier penetration or an ADME/PK profile optimized to achieve target coverage. The compounds show high potency on the mGluR4 target and selectivity over the other mGluR subtypes. We believe that these compounds represent a unique opportunity to build a high quality development pipeline of therapeutics for Parkinson’s disease.